Skip to main content
TipRanks
Go Ultimate75% OFF

TG Therapeutics (TGTX) Stock Price & Analysis

2,177 Followers

TGTX Stock Chart & Stats

$64.88-$1.24(-1.88%)
At close: 4:00 PM EST
$50$55$60$65Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$64.62 - $67.19
52-Week Range
$26.76 - $68.03
Previous Close
$66.12
Volume
N/A
Average Volume (3M)
1.90M
Market Cap
$9.81B
Enterprise Value
$8.95B
Total Cash (Recent Filing)
$504.67M
Total Debt (Recent Filing)
$754.37M
Price to Earnings (P/E)
87.1
Beta
0.35
Next Earnings
Mar 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

BRIUMVI Revenue Growth And Adoption

Sustained sequential growth and expanding new-patient starts indicate that BRIUMVI is building durable commercial traction rather than relying on a single launch period. Continued adoption, persistence, and prescriber expansion can support revenue compounding over the next several quarters.

Durable Clinical Differentiation

Long-term efficacy and safety data strengthen BRIUMVI's value proposition with neurologists, patients, and payors. Evidence that clinical benefits persist over seven years can support treatment retention, physician confidence, and competitive resilience as the multiple-sclerosis market evolves.

Strengthening Capitalization And Leverage

A larger equity base and substantially lower leverage improve TG Therapeutics' financial resilience as it funds commercialization and pipeline development. This stronger capital structure provides more flexibility to invest in growth while reducing the burden of debt-related claims on future cash flows.

Bears Say

Gross-to-net Pressure

Increasing rebates, government discounts, and payer concessions can reduce the net revenue captured from each BRIUMVI treatment even when demand grows. Persistent gross-to-net pressure could limit margin expansion and require greater commercial spending to preserve access and market share.

Anti-CD20 And Oral Therapy Competition

Competition spans both established anti-CD20 drugs and oral therapies that capture many new starts, creating a durable challenge to patient acquisition. Rivals' subcutaneous offerings may also raise convenience expectations and increase contracting or promotional pressure on BRIUMVI.

Inconsistent Cash Conversion

Recent positive cash flow is encouraging, but the history of negative operating and free cash flow shows that earnings have not yet translated consistently into cash. Modest TTM cash conversion could constrain internally funded investment if working-capital or collection dynamics weaken.

TG Therapeutics News

TGTX FAQ

What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $26.76 and its highest was $68.03 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $9.81B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 102 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Nov 09, 2026. The company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.359 by -$0.009.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.52.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 151,147,830 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.35 in its last earnings report, missing expectations of $0.359. Following the earnings report the stock price went up 5.942%.
Which hedge fund is a major shareholder of TG Therapeutics?
Hedge funds hold TG Therapeutics shares: the largest hedge-fund position in TG Therapeutics is 72,326,564 shares, and hedge funds increased their holdings by 803.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology